Compare NSRX & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | UG |
|---|---|---|
| Founded | 2019 | 1942 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 36.5M |
| IPO Year | 2024 | 1995 |
| Metric | NSRX | UG |
|---|---|---|
| Price | $4.10 | $7.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 12.3K | 6.6K |
| Earning Date | 03-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 7.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $10,545,468.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $5.58 |
| 52 Week High | $9.50 | $8.78 |
| Indicator | NSRX | UG |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 51.75 |
| Support Level | $2.90 | $6.92 |
| Resistance Level | $4.49 | $7.42 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 89.52 | 37.42 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.